Live feed21:45:00·4hPRReleasevia QuantisnowEnhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 TrialByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
